Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents by Novohradsky, Vojtech et al.
This journal is©The Royal Society of Chemistry 2017 Chem. Commun., 2017, 53, 5523--5526 | 5523
Cite this:Chem. Commun., 2017,
53, 5523
Somatostatin receptor-targeted organometallic
iridium(III) complexes as novel theranostic agents†
Vojtech Novohradsky,a Ana Zamora,bc Albert Gandioso,b Viktor Brabec, *a
Jose´ Ruiz *c and Vicente Marcha´n *b
A novel somatostatin receptor-targeted anticancer agent based on
the conjugation of a highly cytotoxic and luminescent cyclometalated
iridium(III) complex to tumor-targeting vectors based on octreotide
peptide has been described, and its potential for targeted theranostic
applications has been demonstrated.
During the fight against cancer, chemotherapeutic agents have
to overcome many obstacles that often prevent a successful
outcome of the disease. Indeed, low molecular weight cytotoxic
drugs, either organicmolecules (e.g. camptothecin and doxorubicin)
or metal complexes (e.g. cisplatin and derivatives), cause severe toxic
side eﬀects in patients owing to their poor tumor tissue selectivity.
Low tumor accumulation, poor aqueous solubility and intrinsic or
acquired resistance also contribute to reducing their anticancer
eﬃcacy. In such a context, targeted delivery approaches1 have
emerged as a promising strategy to overcome these drawbacks,
particularly those based on ligands whose receptors are over-
expressed on the surface of malignant cells compared with
healthy cells.1,2 The conjugation of therapeutic agents to target-
ing vehicles based on small regulatory peptides oﬀers several
advantages including the disposal of eﬃcient solid-phase proce-
dures for synthesizing drug conjugates with improved pharma-
cological properties.
Iridium complexes have recently emerged as promising alter-
natives to platinum-based metallo-anticancer drugs.3 Meanwhile,
cyclometalated Ir(III) complexes have gained attention as imaging
and sensing probes due to their rich photophysical properties
and good cell permeability,4 which can be fine-tuned by the
modification of the ligands. For example, the use of the pharma-
cophore benzimidazole as a ligand has given rise to a wide variety
of metal compounds that act either as anti-angiogenic and/or
anti-tumor agents,5 or inhibitors of amyloid-b aggregation.6 The
integration of anticancer activities into cyclometalated Ir(III) com-
plexes provides, therefore, an opportunity for the construction of
novel theranostic platforms. Ir(III) complexes can also function as
eﬃcient photosensitizers for producing singlet oxygen, 1O2, and
can even be developed as organelle-targeted PDT agents.7 Despite
these promising achievements, further work is necessary to
improve the pharmacological properties of Ir(III) metallodrugs,
such as aqueous solubility and selectivity against cancer cells.
In this context, targeted approaches based on peptide vectors
whose receptors are overexpressed on the membrane of tumor
cells compared with normal cells2,8 in combination with light
activation open the door to a new generation of metallo-anticancer
agents with a dual mechanism of selectivity.9
Herein, we have conjugated for the first time a highly cyto-
toxic and luminescent Ir(III) complex, [Ir(ppz)2(N
4N)] (Hppz =
1-phenylpyrazole; N4N = methyl 1-butyl-2-pyridyl-benzimidazole-
5-carboxylate),5a to tumor-targeting vectors based on octreotide
peptide with the aim of increasing cancer cell selectivity and
exploring their potential as novel theranostic agents (Scheme 1).
Octreotide (OCT) is a FDA-approved synthetic cyclooctapeptide
agonist of the endocrine hormone somatostatin that displays high
aﬃnity for the somatostatin subtype-2 receptor (SSTR2).2a It is
metabolically more stable than somatostatin since it incorporates
D-amino acids, and the cysteine bridge stabilizes the pharmaco-
phore sequence (Phe7-D-Trp8-Lys9-Thr10) in a b-turn. As a result,
octreotide binds with high aﬃnity and selectivity to somatostatin
receptors (SSTRs), mainly SSTR2.2a,10 Precisely, the fact that SSTR2
is the most frequently overexpressed somatostatin receptor on the
membrane of many tumor cells led to the use in the clinics of the
[111In-DTPA]-octreotide and [90Y-DOTA-Tyr3]-octreotide conjugates
in molecular imaging and therapy of neuroendocrine tumors,
respectively,2a,10 and several other SSTR2-targeted radiothera-
peutics are currently under clinical evaluation.1a Octreotide has also
been conjugated to cytotoxic organic drugs and metal complexes,
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with promising results because of the reduced toxicity and the
increased selectivity.11
The attachment of the Ir(III) complex to octreotide was
designed through the formation of an amide bond between a
carboxylic function in the benzimidazole diimine ligand and
the N-terminal end of the peptide sequence (Scheme 1). The
incorporation of a spacer is essential to keep the metal complex
away from the pharmacophore sequence and the b-turn peptide
structure, which are key elements for recognition and binding
to the receptor.11b Besides octreotide, we also selected a dicarba
analogue (dcOCT), since the replacement of the disulfide bond
by a CH2–CH2 linkage increases stability in the reductive cellular
environment without significantly altering the binding affinity
for somatostatin receptors.11b,c,12
First, the ester function of the parent cyclometalated Ir(III)
complex 15a was hydrolyzed with LiOH to aﬀord complex 2
(Scheme 1) bearing the carboxylic function suitable for conju-
gation. Taking into consideration the advantages of solid-phase
peptide synthesis (SPPS), the synthesis of the Ir–OCT (5) and
Ir–dcOCT (6) conjugates was planned through a stepwise solid-
phase strategy in which the metallic moiety is regioselectively
attached at the N-terminal end of the resin-bound peptide
(Scheme 2). In both cases, the linear peptide sequences were
assembled manually on a Rink amide resin-p-MBHA using standard
Fmoc-tBu methodology (Scheme 2).11b,c In the case of 5, after
the attachment of 2, side-chain deprotection and cleavage from
the resin afforded the linear conjugate, which was cyclized via
disulfide bond formation. On the other hand, once the linear
dicarba analogue of octreotide, where both cysteines are replaced
by allyl glycine residues, had been assembled, on-resin microwave-
assisted ring-closing metathesis with a second-generation Grubbs
catalyst followed by hydrogenation using Wilkinson’s catalyst
afforded the protected dicarba analogue of octreotide bound to
the resin (Scheme 2).11b,c Finally, after the incorporation of 2,
acidic treatment afforded directly 6. Both conjugates were purified
by reversed-phase HPLC and fully characterized by HR ESI-MS,
UV-vis and fluorescence spectroscopy (Fig. S3–S8, ESI†). Impor-
tantly, the aqueous solubility of 1was substantially improved upon
peptide derivatization since both conjugates were found to be
completely soluble in PBS buffer.
Having at hand Ir–octreotide conjugates, we first studied the
expression levels of the hSSTR2 receptor in a panel of cancer
cell lines to choose the best model for assessing the capacity of
the peptides to deliver the Ir(III) drug in a selective manner. As
shown in Fig. S9 and Table S1 (ESI†), HeLa cervix carcinoma
cells expressed high levels of hSSTR2 while MDA-MB-231 breast
cancer cells expressed low levels and, therefore, they can be
used as positive and negative controls of cells over-expressing
SSTR2, respectively. Next, the efficiency of intracellular delivery
of octreotide, OCT, and of the dicarba analogue, dcOCT, was
studied in HeLa cells by flow cytometry by using the corres-
ponding fluorescein-labeled peptides.11b As previously found by
us in MCF-7 cells,11b the internalization of FITC-OCT was slightly
higher compared with that of FITC-dcOCT, which correlates with
the lower binding affinity of dcOCT for SSTR2 compared with
OCT (Fig. S10, ESI†).10a,12
Since the cytotoxic activity of metal-based anticancer drugs
is highly dependent on cellular uptake and accumulation, we
studied the eﬀect of peptide conjugation on the accumulation
of the Ir(III) complex as well as the participation of SSTR2 in this
process. For this purpose, the accumulation of the Ir–octreotide
conjugates (5 and 6) was studied in HeLa and MDA-MB-231
cancer cells and compared with that of the parent complexes
(1 and 2). Iridium accumulation was quantitatively determined
by ICP-MS after a 2 h exposure treatment to 5 mM of the com-
pounds at 37 1C (Tables S2 and S3, ESI†). As shown in Fig. 1,
complex 1 accumulates much better than the rest of the com-
pounds in both cell lines, which can be attributed both to its
high hydrophobicity and to its cationic nature.5a By contrast,
the accumulation of complex 2 bearing the carboxylic function
was almost negligible in both cell lines. Although Ir–octreotide
conjugates accumulate to a lesser extent than 1, in both cases
the accumulation was slightly higher in HeLa (SSTR2+) than in
MDA-MB-231 (SSTR2) cells. As expected from the low binding
affinity of dcOCT for SSTR2 compared with OCT,12 conjugate 50
accumulation was higher than that of conjugate 6. In order to
get more insights into the cellular uptake of the compounds,
we repeated Ir accumulation studies at 4 1C. As previously
described for other Ir(III) complexes,4d,7b the incubation of HeLa
and MDA-MB-231 cells with 1 at low temperature led to a
reduction in the Ir accumulation, which indicates that 1 enters
the cells through an energy-dependent pathway and not exclu-
sively by passive diffusion. Very interestingly, the accumulation
Scheme 1 (A) Structure of the cyclometalated Ir complexes (1 and 2) and
octreotide (3) and its dicarba analogue (4). (B) Schematic representation of
the Ir–octreotide conjugates (5 and 6).
Scheme 2 Schematic representation of the solid-phase approach used
for the synthesis of the Ir–OCT (5) (A) and Ir–dcOCT (6) (B) conjugates.
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of 5 and 6 was reduced in SSTR2+ HeLa cells at 4 1C, thereby
indicating internalization through an SSTR2-mediated energy-
dependent endocytic mechanism. However, the accumulation
of the Ir–octreotide conjugates in the SSTR2 MDA-MB-231
cells was not influenced when lowering the temperature, which
could suggest the participation of other penetration mechanisms.
These results are not surprising since the nature of the targeted
drug and of the linker can strongly influence not only peptide–
receptor binding but also tumor penetration, metabolism and
excretion of the conjugate.1a
Taking into account the above-mentioned results, we carried
out competitive studies with somatostatin to further confirm
the involvement of SSTR2 in the internalization of the conju-
gates. As shown in Fig. 1C, the pre-treatment of HeLa cells with
somatostatin led to a concentration-dependent reduction of the
accumulation of both conjugates, which confirms the partici-
pation of SSTR2. As expected, neither Ir accumulation from
complex 1 or 2 nor Pt accumulation from cisplatin was aﬀected
by the presence of somatostatin. Interestingly, accumulation in
HeLa cells at diﬀerent time periods revealed a significant drop
in the total cellular Ir accumulation after 24 h, which suggests
that the Ir compounds or their metabolites are good substrates
for p-glycoprotein or some other alternative detoxification mecha-
nisms (Fig. 1D).
Cytotoxicity studies were performed in HeLa and MDA-MB-231
cells to estimate the in vitro antitumor potential of Ir–octreotide
conjugates (5 and 6) and of the parent complexes (1 and 2) and
peptides (OCT and dcOCT). The photobiological activity of the
compounds was also assessed via irradiation with visible light.
In both cases, the MTT assay was performed after 24 h (Table 1)
or 72 h (Table S4, ESI†). Not surprisingly, complex 1 displayed
the highest activity under all the tested conditions,5a and visible
light irradiation leads to a slight improvement of the IC50. In
contrast, complex 2 did not display antiproliferative activity.
These results correlate well with the accumulation data of both
complexes determined by ICP-MS. The conjugation of the Ir(III)
complex to the peptide moieties reduced the cytotoxic activity
of 1 in both cell lines, which again correlates with the reduced
accumulation. However, the activity that the conjugates retain
is still reasonable for a drug–peptide conjugate, specially taking
into account that their efficacy depends not only on the potency
of the therapeutic cargo but also on several factors such as the
number of receptors available to mediate internalization, the
receptor recycling rate, the binding affinity of the peptide for
its receptor when conjugated to the drug cargo or endosomal
sequestration, among others.1a Overall, both conjugates showed
similar antitumor activities which attest the CH2–CH2 linkage as
a suitable isostere for the disulfide bond. Even so, Ir–OCT was
about 2–3 times more active than Ir–dcOCT and was capable of
distinguishing between HeLa and MDA-MB-231 cells after 24 h,
being more active in the SSTR2-overexpressing cell line. This is
particularly appealing since the parent complex 1 was more active
(about 2.5-fold) in the SSTR2 MDA-MB-231 cells. Similarly to
complex 1, visible light irradiation drives to a moderate improve-
ment of the antitumor activities of the conjugates, enough
however to balance the activity reduction that conjugation
involves. Interestingly, the cytotoxic activity of conjugate 5 after
24 h was slightly lower in the non-malignant CHO-K1 cell line
than in tumor HeLa cells (Table S4, ESI†). Octahedral Ir(III)
complexes are characterized for being highly photostable, so
that they are rarely used in PACT7a while the generation of
reactive oxygen species (ROS) is the main mechanism for their
PDT-initiated cell death. Therefore, the intracellular production
of ROS was studied in HeLa cells, either in the dark or after
visible light irradiation. As shown in Fig. S11 (ESI†), the cellular
ROS generation was higher after light irradiation, which sug-
gests that disruption of the mitochondrial function could also
be involved in their mechanism of action. As expected, ROS
production from the parent complex 1 was higher than that of
the Ir–octreotide conjugates, which again correlates with higher
accumulation.
Conjugates between targeting ligands and highly cytotoxic
luminescent complexes are attractive candidates for the develop-
ment of novel theranostic agents13 combining within one mole-
cular system a potent cytotoxic eﬀect with cell targeting and
imaging capabilities. In this context, we have recently found that
Ir(III) complexes of the type 1 mainly accumulate in the cyto-
plasm, specifically in the actin cortex.5a Based on these pre-
cedents, the cellular localization of the Ir–octreotide conjugates
Fig. 1 Accumulation studies of Ir compounds (5 mM) determined by ICP-MS
in HeLa (A) andMDA-MB-231 (B) cells after treatment for 2 h at 37 1C or 4 1C.
(C) Accumulation of Ir compounds and cisplatin (5 mM, 2 h, 37 1C) deter-
mined by ICP-MS in HeLa cells. Cells were first pre-treated for 1 h with
somatostatin at increasing concentrations. (D) Kinetics of cellular accumula-
tion of Ir compounds in HeLa cells after incubation at 1 mM for the indicated
time period at 37 1C. Results are the mean  SDs from three independent
experiments.
Table 1 IC50 (mM) of the compounds tested after 2 h of incubation with
the cells followed by 24 h of the recovery time in drug-free mediaa
HeLa MDA-MB-231
Dark Irradiated PIb Dark Irradiated PIb
1 3.13  0.21 1.25  0.11 2.5 1.23  0.09 0.91  0.08 1.4
2 4200 4200 nd 4200 4200 nd
5 30.9  2.7 15.5  2.5 2.0 49.2  4.1 41.9  4.4 1.2
6 57.8  4.9 53.1  5.1 1.1 51.0  3.3 36.7  2.8 1.4
OCT 4200 4200 nd 4200 4200 nd
dcOCT 4200 4200 nd 4200 4200 nd
a Results are the means  SDs from three independent experiments.
b PI: phototoxic index (IC50 of non-irradiated cells/IC50 irradiated cells).
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was studied by laser scanning confocal microscopy in HeLa cells
with the aim of exploring their potential as targeted theranostic
agents. As shown in Fig. 2 and Fig. S12 (ESI†), the emission
of the Ir(III) complex allowed the visualization of luminescent
vesicles in the cytoplasm, most likely endosomes, confirming the
cellular uptake of the Ir–octreotide conjugates by HeLa cells.
Slightly lower cellular accumulation in MDA-MB-231 cells was
reflected from the reduced intensity of the luminescence signal
compared to that of HeLa cells (Fig. S13, ESI†).
In summary, we have described the synthesis of novel
somatostatin-targeted anticancer agents based on the conjuga-
tion of a cyclometalated luminescent Ir(III) complex to octreotide
vehicles, and demonstrated their potential as targeted theranostic
agents. On the one hand, Ir–octreotide conjugates accumulate
in cancer cells overexpressing SSTR2, and the participation of the
receptor was confirmed by competitive experiments. Such differ-
ences in accumulation between SSTR2+ and SSTR2 cancer cell
lines allowed the modification of the cytotoxicity of the parent Ir
complex, since the conjugates were more active in HeLa cells than
in MDA-MB-231 cells, which is the opposite tendency found with
1. Notably, peptide vehicles (OCT and dcOCT) were non-cytotoxic
and the cytotoxicity was increased in all cases upon visible light
irradiation and ROS production was confirmed. On the other
hand, the internalization of the Ir–octreotide conjugates could be
easily visualized by confocal microscopy owing to the lumines-
cence properties of the Ir(III) complex. Overall, these results open
up the door to the design of novel theranostic agents based on
Ir–peptide conjugates with improved tumor selectivity. Future
work is directed to the optimization of the compounds by
improving the potency and photophysical properties of the
cyclometalated Ir(III) complex through ligand modifications5a
as well as by exploring the use of more hydrophilic or cleavable
linkers to improve their pharmacological properties.1a
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and Competitiveness and FEDER funds (Projects CTQ2015-64319-R
and CTQ2014-52658-R), the Czech Science Foundation (Grant
17-09436S), COST CM1105, CM1406 and the MetDrugs network
(CTQ2015-70371-REDT). A. Z. thanks Fundacion Se´neca-CARM
for a grant (Exp. 19020/FPI/13).
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